




LIVE VIRTUAL EXPERIENCE

Advances in Neurofibromatosis:

INTEGRATING MULTI-MODALITY THERAPY

Friday, October 9, 2020

8:50 AM - 4:15 PM



Memorial Sloan Kettering
Cancer Center

OVERVIEW

The conference is intended to provide an update on current evaluation and multi-modality therapy for neurofibromatosis.

Neurofibromatosis represents a group of inheritable disorders that require multi-disciplinary integrated care. Major advances in defining molecular alterations and developing targeted therapies have changed the landscape of treatment, but require continued laboratory and clinical investigations.

Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) are pursuing numerous areas of investigation in the clinic and laboratory and we anticipate will become one of the driving forces in the development of newer therapies for both benign and malignant tumors (eg MPNST) in NF-associated tumors. Additionally, MSK is one of the most active surgical groups in the world with the recent integration of advanced technologies such as DaVinci robot resection of paraspinal benign tumors.

LIVE VIRTUAL EXPERIENCE

We are excited to announce that this course will now be delivered as a virtual experience. By registering for the live virtual course, you will be able to view presentations, hear live audio, and interact online.

All sessions presented live on Friday, October 9, 2020, will be recorded and made available to attendees for viewing after the course. CME credit will be offered for this course and a certificate will be available after a post-course evaluation is complete.

This live virtual course will be delivered using Zoom. We encourage all attendees to download the Zoom app prior to the start of the course (zoom.us/download). Additional access details will be emailed to all attendees before the course.

MSK COURSE DIRECTORS



Mark Bilsky, MD

Attending Neurosurgeon
Chief, Multi-Disciplinary Spine Tumor Service



Matthias Karajannis, MD, MS

Chief, Pediatric Neuro-Oncology Service



Ori Barzilai, MD

Assistant Attending Neurosurgeon



Anna Piotrowski, MD

Assistant Attending Neuro-Oncologist

MSK COURSE FACULTY

Edmund Bartlett, MD

Assistant Attending Surgeon

Aimee Crago, MD, PhD

Associate Attending Surgeon

Amitabh Gulati, MD

Associate Attending Physician
Director, Chronic Pain

Jonathan Landa, DO

Associate Attending Radiologist

Luis Parada, PhD

Director, Brain Tumor Center

Daniel Prince, MD, MPH

Assistant Attending Surgeon

Samuel Selesnick, MD

Attending Surgeon (WCMC, MSK)
Vice Chairman, Department of Otolaryngology -
Head & Neck Surgery

William Tap, MD

Chief, Sarcoma Medical Oncology Service

Michael Walsh, MD

Assistant Attending Geneticist and
Pediatric Oncologist

Yoshiya (Josh) Yamada, MD

Attending Radiation Oncologist

LIVE VIRTUAL SCHEDULE

All times are Eastern Standard Time (EST)

8:50 AM	VIRTUAL COURSE CHECK-IN
SESSION I • NF1/MPNST MODERATOR: Matthias Karajannis, MD, MS	
9:00 AM	Welcome & Session I Introduction • Mark Bilsky, MD
9:10 AM	Genetics of NF1 • Michael Walsh, MD
9:25 AM	Imaging of NF1 • Jonathan Landa, DO
9:40 AM	NF1 Targeted Therapy • Anna Piotrowski, MD
10:00 AM	Preclinical Models NF1 • Luis Parada, PhD
10:20 AM	BREAK
10:30 AM	Clinical Trials for MPNST • William Tap, MD
10:50 AM	Surgical Management for MPNST • Edmund Bartlett, MD
11:10 AM	NF1-associated Tumors (GIST, Breast) • Aimee Crago, MD, PhD
11:30 AM	Management of Long Bone Dysplasias • Daniel Prince, MD, MPH
11:50 AM	TUMOR BOARD CASE PRESENTERS Aimee Crago, MD, PhD Edmund Bartlett, MD PANELISTS Mark Bilsky, MD William Tap, MD, Yoshiya (Josh) Yamada, MD
12:20 PM	LUNCH BREAK
SESSION II • NF2/Schwannomatosis MODERATOR: Anna Piotrowski, MD	
1:15 PM	Session II Introduction • Mark Bilsky, MD
1:20 PM	Genetics of NF2/Schwannomatosis • Michael Walsh, MD
1:35 PM	Imaging of NF2/Schwannomatosis • Jonathan Landa, DO
1:50 PM	Surgical Management of Vestibular Schwannomas • Samuel Selesnick, MD
2:10 PM	Molecular Targeted Therapies for NF2 • Matthias Karajannis, MD, MS
2:30 PM	Advances in Spine Surgery for Neurofibromatosis • Ori Barzilai, MD
2:45 PM	BREAK
2:55 PM	The Role of Radiation Therapy in NF • Yoshiya (Josh) Yamada, MD
3:15 PM	Pain Management • Amitabh Gulati, MD
3:35 PM	TUMOR BOARD CASE PRESENTER Matthias Karajannis, MD, MS PANELISTS Anna Piotrowski, MD Samuel Selesnick, MD, Yoshiya (Josh) Yamada, MD
4:05 PM	Closing Remarks • Anna Piotrowski, MD
4:15 PM	ADJOURN

Register for the Live Virtual Experience:
mskcc.org/neurofibromatosiscourse

Registration Fees

Physicians (MDs, PhDs and DOs)	\$100
Advanced Practice Providers	\$75
Residents, Fellows, Nurses and Other Healthcare Providers	\$75
Industry Professionals*	\$175

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Registration Discounts/Promotions

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

For additional information and registration details, visit the course website:

mskcc.org/neurofibromatosiscourse

ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **6.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.



Memorial Sloan Kettering
Cancer Center



Advances in Neurofibromatosis:

INTEGRATING MULTI-MODALITY THERAPY

mskcc.org/neurofibromatosiscourse



Memorial Sloan Kettering
Cancer Center